Identification of Immune Checkpoint Inhibitor–Induced Diabetes
The results of this analysis of 14 328 ICI-treated patients followed up from ICI initiation determined the incidence, risk factors and clinical spectrum of ICI-induced diabetes. Widespread implementation of this approach across organ-specific irAEs may enhance diagnosis and management of these conditions, and this becomes especially pertinent as ICI treatment rapidly expands to treat a wide spectrum of cancers and is used at earlier stages of treatment.
Authors
- Kaitlyn Shank
- Gunturi Alekhya
- Aaron J. Deutsch (ORCID: https://orcid.org/0000-0001-6750-5335)
- Caitlin Colling
- Tianqi Ouyang (ORCID: https://orcid.org/0000-0001-5949-0911)
- Kerry L. Reynolds (ORCID: https://orcid.org/0000-0002-7793-654X)
- Natalia Chamorro-Pareja (ORCID: https://orcid.org/0000-0003-1354-1730)
- Leyre Zubiri
- Alexandra–Chloé Villani (ORCID: https://orcid.org/0000-0001-7461-0408)
- Meghan E. Sise (ORCID: https://orcid.org/0000-0002-4327-9713)
- Karen Klahr Miller (ORCID: https://orcid.org/0000-0001-9438-2449)
- Miriam S. Udler (ORCID: https://orcid.org/0000-0003-3824-9162)
- Alexander Gusev (ORCID: https://orcid.org/0000-0002-4579-3062)
- Michelle Rengarajan (ORCID: https://orcid.org/0000-0003-3203-7986)
- Karina Nicole Ruiz-Esteves (ORCID: https://orcid.org/0000-0002-1882-5348)
- Katherine Perlman
- Jose C. Florez
Institutions
- Broad Institute (US)
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Center for Cancer Research (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1001/jamaoncol.2024.3104
- Citations
- 23
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.50